Holding NVAX?
Track your performance easily
Link Broker
9,376 Followers
NVAX Stock Chart & Stats
Advanced Chart >
Day’s Range$0 - $0
52-Week Range$3.53 - $23.86
Previous Close$12.64
Volume4.66M
Average Volume (3M)11.61M
Market Cap
$2.02B
Enterprise Value$1.21B
Total Cash (Recent Filing)$1.05B
Total Debt (Recent Filing)$233.25M
Price to Earnings (P/E)―
Beta2.72
Nov 06, 2024
-$0.9
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.77
Shares Outstanding160,093,639
10 Day Avg. Volume5,701,339
30 Day Avg. Volume11,611,487
Standard Deviation0.51
R-Squared0.04
Alpha0.08
Financial Highlights & Ratios
Price to Book (P/B)-1.97
Price to Sales (P/S)4.87
Price to Cash Flow (P/CF)-5.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.22
Enterprise Value/Gross Profit5.68
Enterprise Value/Ebitda-18.35
Forecast
$18.25
Price Target Upside40.82% Upside
Rating ConsensusHold
Number of Analyst Covering5
Novavax News
PremiumMarket News
NVAX Earnings: Novavax Rallies on Q2 Earnings Beat
11d ago
PremiumThe Fly
Novavax price target lowered to $23 from $25 at B. Riley
8d ago
PremiumThe Fly
Novavax raises 2024 revenue view to $700M-$800M from $400M-$600M
12d ago
PremiumThe Fly
Novavax reports Q2 EPS 99c, consensus $1.64
12d ago
PremiumPress Releases
Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights
12d ago
PremiumPre-Earnings
Novavax (NVAX) Q2 Earnings Cheat Sheet
14d ago
PremiumThe Fly
Affirm, Sprouts Farmers upgraded: Wall Street’s top analyst calls
20d ago
PremiumThe Fly
Novavax downgraded to Underweight from Neutral at JPMorgan
21d ago
Bulls Say, Bears Say
Bulls Say
Commercial ExpansionRetail pharmacy contracts finalized with major chains, regional grocers, merchants, buying groups, and independent chains — a total of 17k+ locations vs. FY23.
Cost StructureRecalibration of cost structure has resulted in OpEx reduction of 34% vs. 2023 and maintaining OpEx FY24 guide of $700-$750M, with plans to initiate further reductions.
Strategic PartnershipNovavax announced it and Sanofi have agreed to co-exclusive co-commercialization of Novavax’ COVID-19 vaccine and develop novel combination influenza plus COVID-19 (CIC) vaccines.
Bears Say
GuidanceDownward revised FY24 guidance, which was lowered to reflect management's decision to exclude future APAs from guidance; these result in FY25-26E revenue estimates to be lowered.
Market OutlookThe outlook for the COVID-19 vaccine market in later years remains murky and the rate at which sales might grow remains increasingly uncertain.
SalesManagement lowered FY24 vaccine sales guidance again now to $275-$375M, largely due to unwinding commercial sales activity in Europe.
---
Financials
Annual
Options Prices
Ownership Overview
14.90% Insiders
12.31% Mutual Funds
28.44% Other Institutional Investors
44.34% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data Available
There is no website visitor data available for this stock.
---
NVAX FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was $3.53 and its highest was $23.86 in the past 12 months.
What is Novavax’s market cap?
Currently, no data Available
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is Nov 06, 2024 which is in 78 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on Aug 08, 2024. The company reported $0.99 earnings per share for the quarter, missing the consensus estimate of $1.67 by -$0.68.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -$0.9.
How many shares outstanding does Novavax have?
Novavax has 160,093,640 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of $0.99 in its last earnings report, missing expectations of $1.67. Following the earnings report the stock price went up 9.057%.
Which hedge fund is a major shareholder of Novavax?
Among the largest hedge funds holding Novavax’s share is Coatue Management, LLC. It holds Novavax’s shares valued at 33M.
---
Novavax Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
7.93%
Trailing 12-Months
Company Description
Novavax
Novavax, Inc. is a late-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. Its vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
---
NVAX Company Deck
---
NVAX Earnings Call
Q2 2024
0:00 /
0:00
---
NVAX Stock 12 Month Forecast
Average Price Target
$18.25
▲(40.82% Upside)
Technical Analysis
Similar Stocks
Company
Price & Change
Follow
INO Inovio Pharmaceuticals
―
―
MRNA Moderna
―
―
BNTX BioNTech SE
―
―
VXRT Vaxart
―
―
Best Analysts Covering NVAX
1 Year
Vernon BernardinoH.C. Wainwright
1 Year Success Rate
20/35 ratings generated profit
1 Year Average Return
+162.03%
reiterated a buy rating 3 months ago
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +162.03% per trade.
Popular Stocks
---
Become an Expert with TipRanks Premium
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis
Subscribe Now
